Is Biogen Stock a Good Investment?

Biogen Investment Advice

BIIB

To provide specific investment advice or recommendations on Biogen Inc stock, we recommend investors consider the following general factors when evaluating Biogen Inc. This will help you to make an informed decision on whether to include Biogen in one of your diversified portfolios:

Examine Biogen's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Biogen's leadership team and their track record. Good management can help Biogen navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Biotechnology space and any emerging trends that could impact Biogen's business and its evolving consumer preferences.
Compare Biogen's performance and market position to its competitors. Analyze how Biogen is positioned in terms of product offerings, innovation, and market share.
Check if Biogen pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Biogen's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Biogen Inc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Biogen Inc is a good investment.

Sell

Buy

Hold

Macroaxis provides advice on Biogen Inc to complement and cross-verify current analyst consensus on Biogen Inc. Our investment recommendation engine determines the company's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon. To make sure Biogen is not overpriced, please confirm all Biogen Inc fundamentals, including its shares owned by institutions, price to sales, net income, as well as the relationship between the price to earning and gross profit . Given that Biogen Inc has a price to earning of 14.83 X, we suggest you to validate Biogen Inc market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Market Performance	Very Weak	Details
Volatility	Very steady	Details
Hype Condition	Over hyped	Details
Current Valuation	Undervalued	Details
Odds Of Distress	Very Low	Details
Economic Sensitivity	Follows the market closely	Details
Investor Sentiment	Alarmed	Details
Analyst Consensus	Strong Buy	Details
Financial Strenth (F Score)	Poor	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Unlikely Manipulator	Details

Examine Biogen Stock

Researching Biogen's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 93.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.42. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biogen Inc recorded earning per share (EPS) of 11.06. The entity had not issued any dividends in recent years. The firm had 3:1 split on the 18th of January 2001.

To determine if Biogen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biogen's research are outlined below:

	Biogen Inc generated a negative expected return over the last 90 days
	Biogen Inc has a poor financial position based on the latest SEC disclosures
	Over 93.0% of the company shares are held by institutions such as insurance companies
	Latest headline from insidermonkey.com: Why Is Biogen Inc. Among the Worst Performing Healthcare Stocks in 2024

Biogen Quarterly Long Term Debt

4.55 Billion

Biogen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biogen Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biogen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	13th of February 2024 Upcoming Quarterly Report	View
	23rd of April 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	13th of February 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

Earnings surprises can significantly impact Biogen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Biogen's investors have experienced.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2000-07-18	2000-06-30	0.08	0.09	0.01	12
1999-04-20	1999-03-31	0.03	0.04	0.01	33
1999-02-09	1998-12-31	0.04	0.05	0.01	25
1998-02-05	1997-12-31	0.05	0.06	0.01	20
1996-10-30	1996-09-30	-0.05	-0.04	0.01	20
2000-02-02	1999-12-31	0.07	0.05	-0.02	28
1998-04-20	1998-03-31	0.01	0.03	0.02	200
1997-11-11	1997-09-30	-0.06	-0.08	-0.02	33

Know Biogen's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biogen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biogen Inc backward and forwards among themselves. Biogen's institutional investor refers to the entity that pools money to purchase Biogen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Beutel, Goodman & Company Ltd.	2024-09-30	1.7 M
Legal & General Group Plc	2024-06-30	1.5 M
Ameriprise Financial Inc	2024-06-30	1.5 M
Goldman Sachs Group Inc	2024-06-30	1.4 M
Northern Trust Corp	2024-09-30	1.4 M
Amvescap Plc.	2024-06-30	1.3 M
Bank Of New York Mellon Corp	2024-06-30	1.2 M
Ra Capital Management, Llc	2024-09-30	1.2 M
Ubs Asset Mgmt Americas Inc	2024-09-30	1.2 M
Vanguard Group Inc	2024-09-30	16.7 M
Primecap Management Company	2024-09-30	16.3 M

Note, although Biogen's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biogen's market capitalization trends

The company currently falls under 'Large-Cap' category with a current market capitalization of 23.41 B.

Market Cap

4.18 Billion

Biogen's profitablity analysis

	Last Reported	Projected for Next Year
Return On Tangible Assets	0.09	0.08
Return On Capital Employed	0.09	0.08
Return On Assets	0.04	0.06
Return On Equity	0.08	0.10

The company has Profit Margin (PM) of 0.17 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.21 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.21.

Determining Biogen's profitability involves analyzing its financial statements and using various financial metrics to determine if Biogen is a good buy. For example, gross profit margin measures Biogen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biogen's profitability and make more informed investment decisions.

Biogen's Earnings Breakdown by Geography

Please note, the presentation of Biogen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biogen's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biogen's management manipulating its earnings.

Evaluate Biogen's management efficiency

Biogen Inc has return on total asset (ROA) of 0.0499 % which means that it generated a profit of $0.0499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1047 %, meaning that it created $0.1047 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.1, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M.

	Last Reported	Projected for Next Year
Book Value Per Share	102.28	107.39
Tangible Book Value Per Share	1.50	1.43
Enterprise Value Over EBITDA	18.40	19.32
Price Book Value Ratio	2.53	2.40
Enterprise Value Multiple	18.40	19.32
Price Fair Value	2.53	2.40
Enterprise Value	6.4 B	4.2 B

The operational strategies employed by Biogen management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.

Beta

(0.06)

Basic technical analysis of Biogen Stock

As of the 30th of November, Biogen shows the Risk Adjusted Performance of (0.20), mean deviation of 1.01, and Standard Deviation of 1.31. Biogen Inc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Biogen's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biogen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Singhal Priya over three months ago Disposition of 1668 shares by Singhal Priya of Biogen subject to Rule 16b-3
		Singhal Priya over six months ago Disposition of tradable shares by Singhal Priya of Biogen at 213.09 subject to Rule 16b-3
		Ginger Gregory over six months ago Disposition of 634 shares by Ginger Gregory of Biogen at 240.98 subject to Rule 16b-3
		Douglas Williams over a year ago Sale by Douglas Williams of 916 shares of Biogen

Biogen's Outstanding Corporate Bonds

Biogen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biogen Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biogen bonds can be classified according to their maturity, which is the date when Biogen Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Dana 575 percent Corp Bond US235822AB96	View
	Volcan Compania Minera Corp Bond USP98047AC08	View
	Boeing Co 2196 Corp Bond US097023DG73	View
	HSBC Holdings PLC Corp Bond US404280DR76	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	BIOGEN INC 52 Corp Bond US09062XAD57	View
	BIOGEN INC 405 Corp Bond US09062XAF06	View
	BIOGEN INC Corp Bond US09062XAG88	View

View All Biogen Corporate Bonds

Understand Biogen's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Biogen's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	(0.20)
	Market Risk Adjusted Performance	(0.54)
	Mean Deviation	1.01
	Coefficient Of Variation	(368.13)
	Standard Deviation	1.31
	Variance	1.7
	Information Ratio	(0.38)
	Jensen Alpha	(0.45)
	Total Risk Alpha	(0.58)
	Treynor Ratio	(0.55)
	Maximum Drawdown	6.36
	Value At Risk	(2.60)
	Potential Upside	1.95
	Skewness	(0.07)
	Kurtosis	0.1735

	Risk Adjusted Performance	(0.20)
	Market Risk Adjusted Performance	(0.54)
	Mean Deviation	1.01
	Coefficient Of Variation	(368.13)
	Standard Deviation	1.31
	Variance	1.7
	Information Ratio	(0.38)
	Jensen Alpha	(0.45)
	Total Risk Alpha	(0.58)
	Treynor Ratio	(0.55)
	Maximum Drawdown	6.36
	Value At Risk	(2.60)
	Potential Upside	1.95
	Skewness	(0.07)
	Kurtosis	0.1735

Consider Biogen's intraday indicators

Biogen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biogen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	21612.39
	Daily Balance Of Power	0.2477
	Rate Of Daily Change	1.01
	Day Median Price	160.06
	Day Typical Price	160.25
	Price Action Indicator	0.97
	Period Momentum Indicator	0.8
	Relative Strength Index	30.6

Biogen Corporate Filings

13A	12th of November 2024 An amended filing to the original Schedule 13G	View Verify
F4	7th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
8K	30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about	View Verify
13A	16th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934	View Verify

Biogen time-series forecasting models is one of many Biogen's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biogen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Biogen Stock media impact

Far too much social signal, news, headlines, and media speculation about Biogen that are available to investors today. That information is available publicly through Biogen media outlets and privately through word of mouth or via Biogen internal channels. However, regardless of the origin, that massive amount of Biogen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of Biogen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biogen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biogen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biogen alpha.

Biogen Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Biogen can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.

Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Biogen Inc Historical Investor Sentiment

Investor biases related to Biogen's public news can be used to forecast risks associated with an investment in Biogen. The trend in average sentiment can be used to explain how an investor holding Biogen can time the market purely based on public headlines and social activities around Biogen Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Biogen's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biogen and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Biogen news discussions. The higher the estimate score, the more favorable the investor's outlook on Biogen.

Biogen Corporate Executives

Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.

Michael CPA

Executive CFO

Profile

When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock: